Searchable abstracts of presentations at key conferences in endocrinology

ea0091wb1 | Workshop B: Disorders of growth and development | SFEEU2023

Lumps, bumps and organ failure following childhood cancer therapy

Berry Simon , Debono Miguel

Background: The late effects of childhood cancer therapy include a higher risk of subsequent primary cancers, fertility issues, and other endocrine dysfunction.Case: A 47 year old woman was treated at age 9 for acute myeloid leukaemia with chemotherapy (DAT, MACE, and cyclophosphamide), total body irradiation (990 cGy) and allogeneic bone marrow transplantation. Aged 22, a rapidly enlarging right sided thyroid nodule developed in the context of a multino...

ea0077p248 | Thyroid | SFEBES2021

Radioactive Iodine Therapy in Benign Thyroid Disease – results from implementing 2007 RCP Guidelines

Berry Simon , Sloan Gordon , Reed Emily , Brown Colleen , Allahabadia Amit

Aim: To evaluate the outcomes of radioactive iodine therapy (RAI) in benign thyroid disease following implementation of 2007 Royal College of Physicians (RCP) guidelines in a large NHS foundation trust.Method: The medical records of patients referred for RAI therapy at Sheffield Teaching Hospitals (UK) between 2013 and 2015 were retrospectively reviewed. Patient data was collected from patientsÂ’ notes and electronic documents system. The data record...

ea0094op5.1 | Adrenal and Cardiovascular | SFEBES2023

Nocturnal metyrapone administration for cortisol suppression in macs: tolerability and impact on metabolic outcomes

Berry Simon , Iqbal Ahmed , Newell-Price John , Debono Miguel

Background: Mild autonomous cortisol secretion (MACS) in patients with adrenal incidentalomas has been associated with elevated cortisol levels during the nocturnal period resulting in a disturbed cortisol rhythm. We hypothesised that administration of nocturnal metyrapone, an 11-beta-hydroxylase inhibitor, previously shown to restore cortisol rhythm in MACS patients, could reduce metabolic complications in this patient group.Met...

ea0094p8 | Adrenal and Cardiovascular | SFEBES2023

A conundrum of steroid absorption and metabolism in the treatment of diamond blackfan anaemia

Berry Simon , Bates Suzanne , Wright Josh , Samuelson Clare , Debono Miguel

Background: Diamond Blackfan anaemia (DBA) is a condition caused by mutations in ribosomal protein genes. After the first year of life, the mainstay of treatment is corticosteroids whilst red blood cell transfusions are used for patients who do not respond.Case: We present a case of a 20-year-old woman with a history of DBA (RPS19 mutation), initially treated with courses of prednisolone, who aged 3 developed steroid-ind...